LakePharma has made various versions of recombinant COVID-19 spike proteins using rapid CHO manufacturing platforms. As a contribution towards combating the current pandemic, LakePharma is making these purified COVID-19 proteins available to the biotech community for rapid antibody and diagnostic development under relaxed business terms.
 
The recombinant COVID-19 spike proteins are produced using LakePharma proprietary TunaCHO manufacturing platforms. They include the full length ectodomain of COVID-19 spike protein in trimeric form with either wild type or prefusion conformation, with or without the furin cleavage site.
 
“LakePharma has been working actively with various partners on approaches against COVID-19 since the end of January,” said Hua Tu, president and chief executive officer, LakePharma. “We have produced several versions of the COVID-19 Spike proteins. We believe they serve as useful reagents for antibody and diagnostic development, and therefore we have made arrangements to make the reagents available to the biotech community. Furthermore, I would like to thank and acknowledge the LakePharma employees who have adapted to this difficult situation and continue to show their dedication to being part of the solution to this global pandemic.”
 
As an essential business exempt from stay-at-home guidance, LakePharma is operating at some of the facilities and has taken great precautions to minimize risks and protect employees, thus continuing the discovery and production of urgently needed biologics.
 
For academic and commercial organizations interested in more information about these proteins and potentially other reagents related to COVID-19, please click here or email kick-covid@lakepharma.com.